Meeting
2023 ASCO Annual Meeting
A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).
Presenter
Erika P. Hamilton, MD
Sarah Cannon Research Institute, Tennessee Oncology, PLLC
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Clinical Trial Registration Number
NCT04699630
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1004)
DOI
10.1200/JCO.2023.41.16_suppl.1004
Abstract #
1004
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2.
Speaker: Nadine M. Tung, MD, FASCO
Videos & Slides
2024 ASCO Annual Meeting
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.
Speaker: Ana Christina Garrido-Castro, MD
Videos & Slides
2024 ASCO Annual Meeting
Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.
Speaker: Yeon Hee Park, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
Tucatinib and trastuzumab for previously treated HER2−mutated metastatic breast cancer (SGNTUC−019): A phase 2 basket study.
Speaker: Paula R Pohlmann, MD, PhD